Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TaiMed BiologicsROCO:4147 +0.63%63 Debt-to-Equity is 0.13 as of Jun. 2026, which is 19% below its 10-year median of 0.16. GuruFocus rates ROCO:4147 with a GF Score™ of 63/100 and a GF Value™ of NT$80.44 (Modestly Undervalued). Among 963 Biotechnology companies, TaiMed Biologics ranks better than 54.52% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TaiMed Biologics's Debt-to-Equity or its related term are showing as below:
ROCO:4147'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.16 Max: 0.29
Current: 0.13
During the past 13 years, the highest Debt-to-Equity Ratio of TaiMed Biologics was 0.29. The lowest was 0.01. And the median was 0.16.
ROCO:4147's Debt-to-Equity is ranked better than 54.52% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs ROCO:4147: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TaiMed Biologics Debt-to-Equity Related Terms
TaiMed Biologics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, TaiMed Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a Debt-to-Equity of 0.13 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TaiMed Biologics and its competitors. This is 19% below median its historical median of 0.16. Over the past decade, TaiMed Biologics' Debt-to-Equity has ranged from 0.01 to 0.29. According to the industry distribution chart, TaiMed Biologics ranks #438 out of 963 companies in the Biotechnology industry, placing it in the top 45.5%.
Is TaiMed Biologics' Debt-to-Equity too high?
TaiMed Biologics' current Debt-to-Equity of 0.13 is 19% below median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.29. The Biotechnology industry median Debt-to-Equity is 0.16. TaiMed Biologics' value of 0.13 is 18.8% below this industry median. Based on the distribution chart, TaiMed Biologics ranks #438 out of 963 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiMed Biologics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #438 out of 963 companies for Debt-to-Equity. This puts TaiMed Biologics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. TaiMed Biologics' value of 0.13 is 18.8% below this benchmark. Historically, TaiMed Biologics' own Debt-to-Equity has ranged from 0.01 to 0.29 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 0.16, TaiMed Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current Debt-to-Equity of 0.13 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current Debt-to-Equity is 0.13, which is 19% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$80.44, compared to a current price of NT$63.60 — trading 20.9% below its estimated fair value. The current Debt-to-Equity is 0.13, which is 19% below median its 10-year median of 0.16 and 18.8% below the Biotechnology industry median of 0.16. TaiMed Biologics' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Debt-to-Equity is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$63.60 is trading 20.9% below its estimated GF Value™ of NT$80.44.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Debt-to-Equity: 0.13 (19% below median its 10-year median of 0.16)
GF Value™: NT$80.44 vs. price of NT$63.60 (20.9% below fair value)
Industry Position: 18.8% below the Biotechnology median (#438 of 963)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
63GF Score
Get the complete analysis for ROCO:4147
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
